by Mark Curtis | Aug 25, 2015
. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...
by Mark Curtis | Aug 18, 2015
. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...
by Stacey Johnson | Aug 14, 2015
. Do you listen to The Stem Cell Podcast? If not, why not? Last September, former Signals co-editor Lisa Willemse blogged about the podcast, which, at the time, was celebrating its first anniversary. The hosts and creators behind the podcast are celebrating another...
by Hamideh Emrani | Aug 10, 2015
. In her series “What drives research in the field of biomaterials?” blogger Hamideh Emrani interviews a third highly respected biomaterials researcher. You can read her interviews with Professors John Davies and Craig Simmons (University of Toronto) here and here. My...
by Mark Curtis | Jul 29, 2015
. Welcome to your Regenerative Medicine Deal Review for the month of June. It was an epic month in partnerships that saw multiple collaborations closely tying industry leaders together. Almost all public cell-based immunotherapy companies have formed partnerships with...
by Paul Krzyzanowski | Jul 23, 2015
. It’s been about 50 years since Philip K. Dick, one of the greatest science fiction authors, introduced the idea of artificial organs replacing failing or diseased organs. In his novel, Ubik, the author writes: “[Glen] Runciter’s body contained a dozen...
Comments